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Abstract
Background: Recombinant T cell receptor ligands (RTLs) are bio-engineered molecules that may serve as novel
therapeutic agents for the treatment of neuroinflammatory conditions such as multiple sclerosis (MS). RTLs contain
membrane distal a1 plus b1 domains of class II major histocompatibility complex linked covalently to specific
peptides that can be used to regulate T cell responses and inhibit experimental autoimmune encephalomyelitis
(EAE). The mechanisms by which RTLs impede local recruitment and retention of inflammatory cells in the CNS,
however, are not completely understood.
Methods: We have recently shown that RTLs bind strongly to B cells, macrophages, and dendritic cells, but not to
T cells, in an antigenic-independent manner, raising the question whether peripheral blood cells express a distinct
RTL-receptor. Our study was designed to characterize the molecular mechanisms by which RTLs bind human blood
platelets, and the ability of RTL to modulate platelet function.
Results: Our data demonstrate that human blood platelets support binding of RTL. Immobilized RTL initiated
platelet intracellular calcium mobilization and lamellipodia formation through a pathway dependent upon Src and
PI3 kinases signaling. The presence of RTL in solution reduced platelet aggregation by collagen, while treatment of
whole blood with RTL prolonged occlusive thrombus formation on collagen.
Conclusions: Platelets, well-known regulators of hemostasis and thrombosis, have been implicated in playing a
major role in inflammation and immunity. This study provides the first evidence that blood platelets express a
functional RTL-receptor with a putative role in modulating pathways of neuroinflammation.
Background
Recombinant T cell receptor ligands (RTLs) represent a
novel, bio-engineered therapeutic drugs for T cell-
mediated autoimmune diseases. RTL molecules consist
of the membrane distal a1p l u sb1d o m a i n so fc l a s sI I
major histocompatibility complex molecules and contain
covalently linked peptide antigen to induce immunosup-
pression by crosslinking to T cell receptor (TCR) in the
absence of co-stimulatory signals [1]. By inhibiting auto-
reactive T cell responses, RTLs have been shown to
reverse the clinical and histological signs in experimental
autoimmune encephalomyelitis (EAE) [2], although the
molecular mechanisms by which RTLs inhibit T cell pro-
liferation and cytokine secretion are still poorly defined.
While RTLs displayed preferential binding to murine
antigen presenting cells (APCs) such as B cells, macro-
phages and dendritic cells, but not to T cells [3], the
binding targets expressed on APCs are currently
unknown.
Blood platelets are classically considered as key regula-
tors of hemostasis. Platelets, however, are also emerging
as modulators in immune responses as well as in the
etiology of neuropathologies [4]. Platelets possess a wide
array of adhesion receptors and secretory products, con-
sisting of chemokines and cytokines [5]. It has been pro-
posed that platelets partner with leukocytes to amplify
the immune response at sites of tissue repair or inflam-
mation [6,7]. Along these lines, in a murine model of
pulmonary acute lung injury, blockade of platelet-
derived thromboxane reversed disease progression, while
pharmacological inhibition of platelet-leukocyte interac-
tions with P-selectin antibodies reduced pulmonary
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let-specific markers such as P-selectin and platelet
microparticles in MS patients [10,11] suggests that pla-
telets may contribute to the pathophysiology of MS
[4,12]. Thus, pharmacological regulation of platelet
function may represent a potential therapeutic strategy
for the treatment of neurovascular inflammation.
Materials and methods
Reagents
Plasma-derived fibrinogen was from Enzyme Research
Laboratories, Inc. (South Bend, IN, USA). RTL1000 and
RTL551 was synthesized as previously described [13].
Anti-factor XI mAb was generated and purified as
described [14]. All other reagents were from Sigma-
Aldrich, Inc. (St. Louis, MO, USA) or previously named
sources [15].
Preparation of purified platelets
Human venous blood was collected from healthy volun-
teers into sodium citrate (final concentration 0.38% vol/
vol) and acid/citrate/dextrose (ACD, 10% vol/vol) to pur-
ify the platelets as previously described [15]. Briefly, pla-
telet-rich plasma (PRP) was prepared by centrifugation of
whole blood at 200 g for 20 minutes. The platelets were
isolated from PRP by centrifugation at 1000 g for 10 min-
u t e si nt h ep r e s e n c eo fp r o s t a c y c l i n( 0 . 1μg/ml). After
centrifugation, purified human platelets were resus-
pended in modified Tyrode’s buffer (129 mM NaCl, 0.34
mM Na2HPO4,2 . 9m MK C l ,1 2m MN a H C O 3,2 0m M
HEPES, 5 mM glucose, 1 mM MgCl2;p H7 . 3 ) .M o u s e
platelets were purified as previously described [16].
Static adhesion assays
Glass coverslips were incubated with a 50 μg/ml solu-
tion of RTL1000 or fibrinogen for 1 hour at room tem-
perature. Surfaces were then blocked with denatured
fatty acid-free bovine serum albumin (BSA, 5 mg/ml)
for 1 hour and washed with phosphate-buffered saline
(PBS). Purified human or mouse platelets (2 × 10
7/ml)
were incubated on the protein-coated coverslips at 37°C
for 45 minutes. Platelet spreading was imaged using
Kohler illuminated Nomarski differential interference
contrast (DIC) optics with a Zeiss 63× oil immersion
1.40 NA plan-apochromat lens on a Zeiss Axiovert 200
m microscope (Carl Zeiss). Images were collected and
processed using Stallion 4.0 (Intelligent Imaging Innova-
tions Inc, Denver, CO). The degree of platelet adhesion
and surface area of bound platelets was quantified using
Image J software as previously described [16].
Fluorescent binding assay
RTL1000 and RTL551 was processed using Zeba™ Desalt
Spin Column (Thermo Fisher Scientific, Waltham, MA)
for buffer-exchange, retained in 50 mM HEPES accord-
ing to the manufacturer’s instruction and labeled with
Alexa Fluor® 488 using Alexa Fluor® 488 labeling kit
(Invitrogen, Carlsbad, CA). Labeled RTL1000 and
RTL551 (RTL1000-Alexa488 and RTL551-Alexa488,
respectively) were processed using the spin column and
recovered in 20 mM Tris (pH 8.4). The yield of the
fluorescent protein was confirmed by measuring OD480
and OD290. Purified human or mouse platelets were
incubated at 37°C for 30 min on fibrinogen-coated glass
coverslips followed by washing with PBS. RTL1000-
Alexa488 or RTL551-Alexa488 (20 μg/ml) in BSA
(1 mg/ml) solution was then loaded over the adherent
human or mouse platelets, respectively, and incubated at
37°C for 30 min. Fluorescence was recorded with a Zeiss
Axiovert inverted fluorescent microscope.
Single platelet Ca
2+ measurements
Platelets were loaded with 15 μM Oregon Green
BAPTA1-AM (Molecular Probes, Eugene, OR) as pre-
viously described [17]. Loaded platelets were allowed to
sediment onto RTL- or fibrinogen-coated coverslips
over a period of 30 min at 37°C. Fluorescent intensities
in single platelets were recorded and analyzed using a
custom Matlab program.
Western blotting and phosphorylation studies
Purified human platelets were incubated for 45 minutes
on protein-coated 24 well plates and lysed with an ice-
cold lysis buffer (20 mM Tris, 300 mM NaCl, 2 mM
EGTA, 2 mM EDTA, 2% NP-40 pH 7.5, containing
Roche Complete Protease Inhibitor Cocktail). Lysates
were separated by SDS-PAGE and transferred onto
PVDF membranes. The membranes were blocked with
5% BSA for 1 hour prior to incubation with primary
antibodies overnight at 4°C. Following washing with
TBS-T, membranes were incubated with the appropriate
secondary antibodies. Subsequent immunoblotting was
carried out as previously described [18].
Platelet aggregation and clotting time measurements
Platelet aggregation was assayed using 300 μl of washed
platelets (2 × 10
8/ml) in a Chrono-Log aggregometer
(Chrono-Log, Havertown, PA) with continuous stirring
at 1200 rpm at 37°C. Activated partial thromboplastin
time (aPTT) of pooled human platelet-poor plasma
(PPP) and recalcification time of PPP were measured
with a KC4 Coagulation Analyzer (Trinity Biotech PLC,
Co Wicklow, Ireland). Samples were pre-treated with
either vehicle, RTL1000 (10 μg/ml), an anti-FXI mAb
(14E11, 20 μg/ml) or tissue factor (TF, 1 pM) for 3 min
prior to the addition of 16.6 mM CaCl2 for recalcifica-
tion times or aPTT reagent (Helena Laboratories,
Beaumont, TX) followed by 6.6 mM CaCl2 for aPTT
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the addition of CaCl2 as previously described [14].
Capillary occlusion assay
Capillary tubes were coated with fibrillar collagen,
aligned vertically and connected to a reservoir as pre-
viously described [14]. Sodium-citrate (0.38% w/v) antic-
oagulated whole blood was sequentially supplemented
with 7.5 mM Ca
2+ and 3.75 mM Mg
2+. Capillary flow
was driven by the force of gravity, and the height of the
sample reservoir was regulated in order to produce an
initial shear rate of 300 s
-1 as previously described [19].
Analysis of data
Data are shown as means ± SEM. Statistical significance
of differences between means was determined by
ANOVA. If means were shown to be significantly differ-
ent, multiple comparisons were performed by the Tukey
test. Probability values of P < 0.05 were selected to be
statistically significant.
Results
Characterization of RTL as a ligand for platelets
To determine the ability of human blood platelets to
support RTL1000 binding, purified platelets were immo-
bilized on a surface of fibrinogen prior to exposure to
fluorescently-labeled RTL1000. RTL1000 bound to the
human platelet surface (Figure 1A), demonstrating that
a receptor for RTL may be present on the surface of
human platelets. In an attempt to identify a potential
RTL-receptor on platelets, washed human platelets were
incubated over RTL-coated glass coverslips, and platelet
adhesion and spreading was monitored with Nomarski
differential interference contrast (DIC) microscopy. Our
data show that RTL1000 supported human platelet sur-
face adhesion and lamellipodia formation (Figure 1B).
The degree of adhesion observed was similar to that of
platelet adhesion to an immobilized surface of fibrino-
gen, which supports platelet adhesion through the aIIbb3
integrin. Minimal platelet adhesion was observed on
BSA-coated coverslips (Figure 1B).
A parallel series of experiments was performed with
purified mouse platelets. RTL551 contains the peptide
derived from mouse myelin oligodendrocyte glycoprotein
(MOG33-35) [3]. Our data demonstrate that fluorescently-
labeled RTL551 bound to the mouse platelet surface, yet
only following stimulation of mouse platelets with the G
protein-coupled agonist, thrombin (Figure 2A). Immobi-
lized RTL551 supported mouse platelet surface adhesion
and lamellipodia formation (Figure 2B). Consistent with
previous reports, mouse platelets exhibit only partial
spreading on a fibrinogen surface (Figure 2B).
RTL supports platelet actin cytoskeletal reorganization
and Ca
2+ mobilization
Upon activation, platelets rapidly mobilize intracellular
stores of calcium and assemble actin-rich structures such
as filopodia, lamellipodia and stress fibers. Fluorescent
labeling of the actin cytoskeleton showed the formation
of stress fibers in the human platelets on immobilized
Figure 1 Characterization of RTL1000-human platelet binding. A) Immobilized human platelets (2 × 10
7/ml) were incubated with
fluorescently-labeled RTL1000 (RTL1000-Alexa488, 20 μg/ml) for 30 min at 37°C. Cells were imaged using differential interference contrast (DIC)
and fluorescent microscopy. B) Washed human platelets (2 × 10
7/ml) were pipetted onto surfaces coated with RTL1000 (50 μg/ml) or fibrinogen
(FG; 50 μg/ml) for 45 min at 37°C.
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loaded with the calcium-reporter dye, Oregon Green
BAPTA 1-AM, revealed that platelets generated a rapid
burst of oscillating intracellular Ca
2+ following binding to
RTL1000, which subsequently declined over a period
of 3-10 min (Figure 4). In contrast, a rhythmic series of
Ca
2+ spikes were observed on fibrinogen (Figure 4).
Characterization of the platelet signaling cascade
downstream of RTL
We next aimed to determine the intracellular mechan-
isms that mediate human platelet spreading on RTL1000.
Addition of the ADP-scavenger apyrase in combination
with the cyclooxygenase inhibitor indomethacin had
no effect on platelet spreading on RTL1000 (Table 1).
In contrast, treatment of platelets with inhibitors
to Src kinases (PP2, 20 μM), Syk kinase (BAY 61-3606,
20 μM), PI3 kinases (wortmannin, 100 nM), protein
kinase C (R0 31-8220, 20 μM) or an intracellular Ca
2+
chelator (BAPTA-AM, 10 μM) abrogated platelet
lamellipodia formation on RTL1000-coated surfaces.
Platelet lamellipodia formation on RTL1000 was also
inhibited in the presence of the aIIbb3 receptor antago-
nist, eptifibatide, whereas adhesion to fibrinogen was
Figure 2 Characterization of RTL551-mouse platelet binding. A) Immobilized mouse platelets (2 × 10
7/ml) were incubated with
fluorescently-labeled RTL551 (RTL551-Alexa488, 20 μg/ml) for 30 min at 37°C. In selected experiments, mouse platelets were stimulated with
thrombin (1 U/ml). Cells were imaged using differential interference contrast (DIC) and fluorescent microscopy. B) Washed mouse platelets (2 ×
10
7/ml) were pipetted onto surfaces coated with RTL551 (50 μg/ml) or fibrinogen (FG; 50 μg/ml) for 45 min at 37°C.
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Table 1)
We next determined whether the interaction of
RTL1000 with human platelets led to the activation of
signal transduction pathways with known roles in plate-
let adhesion and spreading. Platelet binding to RTL1000
was associated with an increase in total tyrosine phos-
phorylation levels as compared to platelets under con-
trol conditions (platelets in solution over BSA) (Figure
6A). The addition of the ADP-scavenger apyrase
reduced the degree of tyrosine phosphorylation in whole
cell lysates as well as the phosphorylation of Akt and of
GSK3b ( F i g u r e6 A ,Ba n d6 C ) .T h eS r cf a m i l yk i n a s e
inhibitor, PP2, the PI3 kinase inhibitor, wortmannin, or
the Syk kinase inhibitor, BAY 61-3606, abrogated phos-
phorylation of Akt and GSK3b (Figure 6B and 6C). In
contrast, phosphorylation of Akt and GSK3b was not
affected by the protein kinase C inhibitor, R0 31-8220
(Figure 6B and 6C).
Effect of RTL on platelet aggregation, coagulation and
occlusive thrombus formation
Next we determined the effect of RTL on the initiation
of coagulation. RTL1000 did not affect the activated par-
tial prothrombin time (aPTT) or the clotting time of
platelet-poor plasma (PPP) initiated by the addition of
excess molar Ca
2+ (Figure 7A and 7B, respectively). In
contrast, the addition of the anti-FXI mAb, 14E11, pro-
longed the aPTT (Figure 7A), while the addition of tis-
sue factor (TF, 1 pM) drastically reduced clotting time
in recalcified plasma (Figure 7B).
To assess the effect of RTL on platelet function, a
solution of purified human platelets was treated with
RTL under constant stirring in an aggregometer. Platelet
aggregation induced by the platelet agonist, collagen,
was inhibited by the addition of RTL1000 (29% aggrega-
tion vs. 20% aggregation after 2 min in the presence of
vehicle or RTL1000, respectively; Figure 7C). Addition
of RTL1000 alone failed to initiate either platelet shape
changes or aggregation (data not shown).
We next investigated the effect of RTL on occlusive
thrombus formation. Recalcified blood was driven by a
constant pressure gradient through collagen-coated
capillaries at an initial shear rate of 300 s
-1,a n df l o w
through the capillary was monitored until occlusion.
Our data demonstrate that RTL substantially prolonged
the time to occlusion (19.5% vs. 26.3% increase with
respect to vehicle for 10 μg/ml RTL or 50 μg/ml RTL,
respectively; Figure 7D). Taken together, these findings
provide the first evidence that RTL-platelet binding may
negatively regulate platelet function and prolong occlu-
sive thrombus formation.
Discussion
Multiple sclerosis is regarded as a prototypical disease
state resultant of neuroinflammation. RTLs have been
engineered to augment antigen-driven immunosuppres-
sion of autoreactive T cells by presenting TCR ligands
(self-antigen plus MHC molecule) in the absence of co-
stimulatory signals that are normally supplemented by
antigen presenting cells (APCs) [1]. RTLs have been
shown to reduce T cell-driven encephalitogenicity and
both clinical and histological signs of EAE [2]. Previous
studies suggested that RTLs confer a therapeutic benefit
via the downregulation of T cell-mediated inflammation
[20] and by modifying the permeability of the blood-
brain barrier in a murine model of EAE [21] or ischemic
Figure 3 Platelet cytoskeletal reorganization on RTL1000
surfaces. Platelets bound to RTL1000 or fibrinogen surfaces were
fixed, permeabilized and stained for F-actin using FITC-conjugated
phalloidin. Representative DIC and fluorescent microscopy images
are shown.
Figure 4 Real-time imaging of intracellular Ca
2+ in platelets.
Platelets were loaded with the calcium reporter dye Oregon Green
BAPTA 1-AM and imaged upon contact with RTL1000 or fibrinogen-
coated surfaces. Graphs show the observed fluorescent intensity
(arbitrary units) of a single platelet over the period of 6 minutes.
The arrows indicate the platelets’ arrival at the region of interest.
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Platelet adhesion (cells/mm
2 ×1 0
2) Surface area (μm
2)
Inhibitor/antagonists RTL1000 fibrinogen RTL1000 fibrinogen
vehicle 44.9 ± 1.1 52.8 ± 1.6 35.5 ± 3.1 31.8 ± 1.2
ADP-scavenger/cyclooxygenase inhibitor 33.4 ± 0.5 34.3 ± 0.7 34.5 ± 3.9 32.1 ± 2.2
aIIbb3 antagonist 26.4 ± 0.8 7.9 ± 1.5 17.6 ± 1.8 16.7 ± 2.3
Src kinase inhibitor 26.4 ± 0.8 48.4 ± 1.9 23.7 ± 2.0 20.0 ± 1.5
Syk kinase inhibitor 36.1 ± 0.5 44.0 ± 0.4 19.5 ± 1.9 25.0 ± 1.4
PI3 kinase inhibitor 29.0 ± 0.5 30.8 ± 0.9 26.3 ± 1.7 17.3 ± 1.4
protein kinase C inhibitor 36.7 ± 0.5 53.7 ± 1.7 19.4 ± 2.3 27.3 ± 1.6
intracellular Ca
2+ chelator 11.4 ± 1.1 13.2 ± 1.2 15.5 ± 2.1 17.2 ± 1.4
Purified human platelets (2 × 10
7/ml) were placed on RTL1000- or fibrinogen-coated coverslips for 45 min at 37°C with an ADP-scavenger and cyclooxygenase
inhibitor (apyrase/indometacin, 2 U/ml/10 μM), the aIIbb3 receptor antagonist (eptifibatide, 20 μg/ml), inhibitors to Src kinases (PP2, 20 μM), Syk kinase (BAY 61-
3606, 20 μM), PI3 kinase (wortmannin, 100 nM), protein kinase C (R0 31-8220, 20 μM) or an intracellular Ca
2+ chelator (BAPTA-AM, 10 μM). Values are reported as
mean ± SEM of 50-300 cells.
Figure 5 Characterization of platelet adhesion and spreading on RTL1000. Platelets were pipetted onto glass surfaces coated with RTL1000
or fibrinogen (FG) for 45 min at 37°C and imaged using DIC microscopy. In selected experiments, platelets were pretreated with vehicle, the
ADP scavenger apyrase (2 U/ml) and cyclooxygenase inhibitor indomethacin (10 μM), the integrin aIIbb3 antagonist eptifibatide (20 μg/ml),
inhibitors to Src family kinases (PP2, 20 μM), Syk kinase (BAY 61-3606, 20 μM), PI3 kinases (wortmannin, 100 nM), protein kinase C (R0 31-8220, 20
μM) or an intracellular Ca
2+ chelator (BAPTA-AM, 10 μM).
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systemic chemokines and adhesion molecules on the
CNS endothelium as well as cytokines that switch on
anti-inflammatory effectors rather than increasing anti-
body production by B cells [21]. Although RTLs were
originally thought to act as a partial agonist via TCR
[23], our recent study demonstrated the inability of sple-
nic CD3
+ T cells to bind RTLs. Rather, we found that
RTLs bound APC populations including B cells, macro-
phages, and dendritic cells, in an antigenic-independent
manner [3]. Perhaps RTL-armed splenic APCs suppress
the transfer of EAE by antigen-stimulated T cells.
Alternatively, peripheral blood cells may bind RTL
through an unknown surface receptor distinct from
TCR, indirectly inducing T cell tolerance against self-
antigen. Our study was designed to determine whether
peripheral blood cell populations, such as platelets, can
bind to RTL, thus offering a level of redundancy to
APCs.
Platelets, well-known regulators of hemostasis and
thrombosis, have been implicated in playing an essen-
tial role in inflammation and immunity [5,7]. Activated
platelets shed granules and microparticles which con-
tain a variety of adhesive molecules and immunomo-
dulatory factors, resulting in the localized recruitment
of immune cells under shear. Abnormal platelet activa-
tion (microparticle presence, P-selectin expression, and
increased circulating aggregates) has been documented
in MS patients [11]. A recent gene microarray study
revealed that the platelet aIIbb3 receptor was transcrip-
tionally upregulated in MS chronic lesions [10]. Per-
haps RTL may modulate the pathophysiological role
that platelets play in neurodegenerative diseases such
as MS.
A number of platelet ligands and pathways have been
identified that negatively regulate platelet function. For
instance, recent studies have shown negative regulatory
roles for the platelet ligands semaphorin 3A [24], his-
tone H1 [25], thrombospondin-1 [26], and low-density
lipoprotein [27]. Our current study provides evidence
that RTL, in addition to serving as a platelet ligand, may
serve to negatively regulate agonist-induced platelet
function, as evidenced by the fact that RTL down-regu-
lated platelet aggregation to collagen. Moreover, our
study provides evidence that RTL inhibits occlusive
thrombus formation on collagen-coated surfaces under
physiologically relevant pressure gradients.
Among various platelet surface RTL-receptors, one
potential candidate we identified was CD40, a co-stimu-
latory molecule that regulates lymphocyte signaling
upon antigen presentation. CD40 is known to contribute
to the initiation, activation, and amplification of immune
responses [28]. CD40-CD40 ligand (CD40L, or CD154)
interactions are well described in MS, as CD40L
+
T cells are known to be greatly increased in MS patients
[29,30]. Moreover, CD40 is expressed on platelets and
APCs, but not T cells, in accord with the peripheral
blood populations we have shown to bind RTL. We
therefore tested the hypothesis that CD40 was the plate-
let receptor for RTL. Our preliminary findings demon-
strated that purified platelets from CD40
-/- mice bind to
RTL at the same level as compared to platelets from
wild type mice (unpublished observations, AI and
OJTM), arguing against a role for CD40 as an RTL-
receptor on mouse platelets. Our future efforts will be
focused on identifying the putative RTL-receptor on
Figure 6 Characterization of phosphorylation in platelets
downstream of RTL1000. Human washed platelets were exposed
to BSA, RTL1000, or fibrinogen (FG) surfaces for 45 min at 37°C.
Platelets adherent to RTL1000 or in suspension over BSA were lysed
in ice-cold lysis buffer. Platelet lysates were separated by SDS-PAGE
and immunoblotted for phosphorylation using A) an anti-
phosphotyrosine antibody (4G10), B) anti-Akt antibody, or C) anti-
GSK3b antibody. In selected experiments, platelets were pretreated
with vehicle or the ADP scavenger apyrase (2 U/ml) in the absence
or presence of inhibitors to Src kinases (PP2, 20 μM), PI3 kinases
(wortmannin, 100 nM), protein kinase C (R0 31-8220, 20 μM), or Syk
kinase (BAY 61-3606, 20 μM).
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molecular mechanisms by which RTL binds to peri-
pheral blood cells may better the understanding of the
pharmacokinetics of RTL drug delivery as well as the
further development of RTL for therapy in autoimmune
diseases.
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